Congenital Amegakaryocytic Thrombocytopenia (CAMT) is a rare inherited bone marrow failure disease in young children where the bone marrow no longer produces platelets or megakaryocytes so the child’s blood will not be able to clot should he/she experience bleeding. Over time, the bone marrow may also stop making red blood cells and neutrophils.
Outstanding Care Team
CAMT is a rare disease and not well understood, which makes treating it challenging. The medical team at Seattle Children's, a parent organization of Seattle Cancer Care Alliance, has a long history of successfully caring for children and teens with AMT. These renowned specialists work together to improve your child's quality of life and conquer this disease.
Medical therapy for DBA is provided at Seattle Children's. If your child's health-care team determines that the best course of action is a bone marrow transplant, your child will receive this treatment through Seattle Cancer Care Alliance, ranked first in outcomes in a four-year study by the National Marrow Donor Program (NMDP) that measured one-year survival rates of patients among 122 transplant centers in the United States.